SEARCH

SEARCH BY CITATION

References

  • 1
    Covic, L., A.L. Gresser, J. Talavera, et al . 2002. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA 99: 643648.
  • 2
    Kaneider, N.C., A. Agarwal, A.J. Leger & A. Kuliopulos. 2005. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat. Med. 11: 661665.
  • 3
    Swift, S., A.J. Leger, J. Talavera, et al . 2006. Role of the PAR1 receptor 8th helix in signaling: the 7–8-1 receptor activation mechanism. J. Biol. Chem. 281: 41094116.
  • 4
    Leger, A.J., S.L. Jacques, J. Badar, et al . 2006. Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis. Circulation 113: 12441245.
  • 5
    Covic, L., M. Misra, J. Badar, et al . 2002. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8: 11611165.
  • 6
    Covic, L., B. Tchernychev, S. Jacques & A. Kuliopulos. 2007. Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis. Handbook of Cell-Penetrating Peptides . Taylor & Francis, NY . 245257.
  • 7
    Trivedi, V., A. Boire, B. Tchernychev, et al . 2009. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137: 332343.
  • 8
    Kaneider, N.C., A.J. Leger, A. Agarwal, et al . 2007. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. Nat. Immunol. 8:13031312.
  • 9
    Scheerer, P., J.H. Park, P.W. Hildebrand, et al . 2008. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497502.
  • 10
    Kunishima, N., Y. Shimada, Y. Tsuji, et al . 2000. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407: 971977.
  • 11
    Rondard, P., S. Huang, C. Monnier, et al . 2008. Functioning of the dimeric GABA(B) receptor extracellular domain revealed by glycan wedge scanning. EMBO J. 27: 13211323.
  • 12
    Hlavackova, V., C. Goudet, J. Kniazeff, et al . 2005. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 224: 499509.
  • 13
    Goudet, C., J. Kniazeff, V. Hlavackova, et al . 2005. Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 280: 2438024385.
  • 14
    Hino, N., Y. Okazaki, T. Kobayashi, et al . 2005. Protein photo-cross-linking in mammalian cells by site-specific incorporation of a photoreactive amino acid. Nat. Methods 2: 201206.
  • 15
    Milligan, G. 2009. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. J. Pharmacol. Electronic publication ahead of print.
  • 16
    Rozenfeld, R., N.S. Abul-Husn, I. Gomes & L.A. Devi. 2007. Emerging roles of delta opioid receptors in the regulation of mu opioid receptor function. The Scientific World JOURNAL. 7(S2): 6473.
  • 17
    Abdelhamid, E.E., M. Sultana, P.S. Portoghese & A.E. Takemori. 1991. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 258: 299.
  • 18
    Abul-Husn, N.S., M. Sutak, B. Milne & K. Jhamandas. 2007. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br. J. Pharmacol. 151: 877.
  • 19
    Rozenfeld, R. & L.A. Devi. 2007. Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimers. FASEB J. 21: 24552465.
  • 20
    Esmon, C.T. 2000. Does inflammation contribute to thrombotic events? Haemostasis 30(Suppl. 2): 3440.
  • 21
    Slofstra, S.H., M.F. Bijlsma, A.P. Groot, et al . 2007. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 110: 31763182.
  • 22
    Covic, L., M. Misra, J. Badar, et al . 2002. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8: 11611165.
  • 23
    Boire, A., L. Covic, A. Agarwal, et al . 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303313.
  • 24
    Agarwal, A., L. Covic, L.M. Sevigny, et al . 2008. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 7: 27462757.
  • 25
    Yang, E., A. Boire, A. Agarwal, et al . 2009. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer. Res. 69: 62236231.